CG Oncology (CGON) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed CG Oncology (CGON) over the past year, gaining 68.4% versus a gain of 64.2%. Jazz Pharmaceuticals is the larger company by market cap ($14.44 billion vs $5.61 billion), about 2.6 times the size, while CG Oncology is growing revenue faster (+254.7% vs +4.9%). Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | JAZZ |
|---|---|---|
| Share price | $63.26 | $222.45 |
| Market cap | $5.61B | $14.44B |
| 1-day change | +1.41% | -3.78% |
| YTD return | +50.24% | +35.99% |
| 1-year return | +64.16% | +68.36% |
| 5-year return | — | +64.31% |
| P/E ratio (TTM) | — | 15.25 |
| Forward P/E | — | 8.58 |
| EPS (TTM) | $-2.69 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $4.27B |
| Revenue growth (YoY) | +254.70% | +4.88% |
| Net income (latest FY) | $-161.00M | $-356.15M |
| Operating margin | -4722.13% | -10.08% |
| Net margin | -3985.02% | -8.35% |
| 52-week high | $80.97 | $266.38 |
| 52-week low | $35.80 | $128.80 |
| Distance from 52-week high | -21.87% | -16.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +43.98% | +32.39% |
| Average volume | 887.57K | 850.55K |
| Shares outstanding | 88.64M | 64.91M |
| Employees | 142 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Jazz Pharmaceuticals is about 2.6 times larger than CG Oncology by market value ($14.44B vs $5.61B).
- Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs +4.88%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
CGON vs JAZZ FAQ
Which is bigger, CG Oncology or Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.44B compared with $5.61B for CG Oncology (CGON).
Which stock has performed better over the past year, CGON or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with +64.16% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and Jazz Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for CG Oncology and Biotechnology: Pharmaceutical Preparations for Jazz Pharmaceuticals.